Skip to content

Clinical trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Country / region: Germany Clear all

127 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20024
20039
20046
20055
20062
20073
20081
20095
20106
20114
20127
20137
20144
20155
20163
20176
20187
20198
20202
20212
20222
20233
20242
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed78
Recruiting18
Unknown status11
Terminated10
Active, not recruiting7
Withdrawn3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Goethe University15
Fred Hutchinson Cancer Center8
Novartis Pharmaceuticals8
Amgen7
European Organisation for Research and Treatment of Cancer - EORTC7
Amgen Research (Munich) GmbH5
Kiadis Pharma5
Universitätsklinikum Hamburg-Eppendorf5
Princess Maxima Center for Pediatric Oncology4
Charite University, Berlin, Germany3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma127
Leukemia, Myeloid, Acute36
Leukemia30
Recurrence23
Burkitt Lymphoma21
Lymphoma, Non-Hodgkin21
Leukemia, Lymphocytic, Chronic, B-Cell19
Multiple Myeloma17
Lymphoma16
Lymphoma, Large B-Cell, Diffuse16

Trials

Showing 51 to 75 of 127. Each trial links to its page on Pharma Observatory.

27 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.